Worked with C-suite and an accounting firm to conduct an economic analysis, structure, and implement intercompany payments and agreements in preparation for an IPO of an innovative biotech incubator. The analysis included valuation of a unique biotech development and production facility, R&D, engineering and management services.
Drug pricing rules and tariffs reshape transfer pricing for IP
In the article “Drug Pricing Rules and Tariffs Reshape Transfer Pricing for IP,” published in Bloomberg Tax, CRA’s Transfer Pricing experts Robin Hart and ...